Research resource only — not medical advice. All information is for educational purposes. Consult a qualified physician before considering any peptide research compound.
Audience Hub · Metabolic Optimization · Body Composition · Mitochondrial Function
The Metabolic Research Hub covers peptide compounds that act on pathways governing body composition, glucose metabolism, mitochondrial function, and lipid utilization. Unlike the Longevity Hub (which focuses on GH axis optimization for systemic anti-aging) or the Immune Hub (inflammation and immune modulation), the Metabolic Hub compounds share a common clinical target: the excess adiposity–metabolic dysfunction phenotype that defines much of the chronic disease risk in longevity medicine. These compounds approach that target through mechanistically distinct pathways — from direct lipolysis (AOD-9604) to mitochondrial AMPK activation (MOTS-c) to GHRH-driven visceral fat reduction (Tesamorelin) — and understanding these mechanism differences is essential for appropriate compound selection.
This Hub Contains the Only FDA-Approved Compound in the PeptideReport.ai Compound Library
Tesamorelin (Egrifta SV®) is FDA-approved for the reduction of excess visceral abdominal fat in HIV-infected patients with lipodystrophy. It is the only compound in this hub — and among the very few across any PeptideReport.ai hub — with FDA NDA approval backed by Phase III RCT data. This distinction is clinically significant: Tesamorelin's evidence level and regulatory status are categorically different from the research compounds in the same hub. Practitioners using Tesamorelin in non-approved indications (off-label for age-related visceral fat in non-HIV patients) are acting outside the FDA label while using the most evidence-supported compound in this space.
The hub is organized around three metabolic sub-domains: adipose tissue reduction (AOD-9604, Tesamorelin), mitochondrial and glucose metabolism (MOTS-c, CJC-1295 metabolic cross-effects), and systemic metabolic healing (BPC-157, cross-listed from the Immune/Healing hub for its metabolic and gut-axis relevance). Each compound has a dedicated profile page with full mechanism, evidence, dosing, and monitoring detail. This hub overview functions as the navigator and comparative frame.
Compound Library
Metabolic Peptide Profiles
Each compound in this hub is characterized by its mechanism tier, evidence quality, primary metabolic target, and route of administration. The evidence levels span from FDA-approved Phase III data (Tesamorelin) to preclinical-only (MOTS-c, BPC-157) — a wider evidence gap than in most hubs. Consult individual profiles for full clinical detail.
The compounds in this hub engage metabolic regulation at four distinct levels of the body composition and energy metabolism hierarchy. Understanding which tier each compound acts on guides both combination rationale and monitoring strategy — compounds at different tiers do not compete and may complement; compounds at the same tier may produce additive or redundant effects.
Tier 1 — Mitochondrial
MOTS-c
Acts at the cellular energy sensor level: MOTS-c activates AMPK (AMP-activated protein kinase) — the master metabolic switch that signals low energy availability and redirects cellular metabolism toward oxidative phosphorylation and fatty acid oxidation. Nuclear translocation under stress activates ATF4-target genes involved in oxidative stress resistance and metabolic reprogramming. This is the most foundational metabolic level — upstream of all hormonal and receptor-level mechanisms below.
MOTS-c→AMPK ↑→β-oxidation ↑→Insulin Sensitivity ↑
Tier 2 — Adipocyte Receptor
AOD-9604
Acts directly on adipocyte β3-adrenergic receptors to sensitize them to catecholamine-driven lipolysis, and upregulates hormone-sensitive lipase (HSL) for triglyceride hydrolysis. This is a localized, tissue-level intervention: the metabolic signal is amplified at the adipocyte membrane without engaging the GH-IGF-1 axis. The fat cell becomes more responsive to the body's own lipolytic signals — this is mechanism amplification rather than hormonal intervention.
AOD-9604→β3-AR sensitization→HSL ↑→Lipolysis ↑ (no IGF-1)
Tier 3 — GH Axis
Tesamorelin / CJC-1295
Act at the hypothalamic-pituitary level: GHRHR agonism → pulsatile GH secretion → IGF-1 → systemic body composition effects (visceral fat reduction, lean mass preservation). This is the hormonal tier — effects are mediated through the full GH-IGF-1 axis and are subject to IGF-1 negative feedback. Tesamorelin has Phase III RCT data specifically demonstrating visceral adipose tissue (VAT) reduction. CJC-1295 No-DAC has similar mechanism with less clinical data and primarily applies to body composition protocols.
Tesamorelin/CJC→GHRHR→GH pulse ↑→IGF-1 ↑→VAT ↓
Tier 4 — Systemic Healing
BPC-157
Acts through GH receptor sensitization, NO-VEGF angiogenesis, and gut barrier protection to create an environment favorable to metabolic recovery and tissue repair. The metabolic effects are secondary to its primary healing function — BPC-157 optimizes the substrate for metabolic improvement (gut absorption, tissue repair, reduced inflammatory burden) rather than directly engaging fat oxidation or hormonal pathways. Cross-listed in this hub for gut-metabolic axis relevance.
This hub has the widest evidence disparity of any PeptideReport.ai hub — spanning from Level I FDA-approved (Tesamorelin) to Level V preclinical-only (MOTS-c, BPC-157). The clinical decision to use any compound in this hub must be calibrated to its specific evidence tier; using Tesamorelin and MOTS-c interchangeably as "metabolic peptides" ignores a 4-level evidence gap with direct informed consent implications.
Level I · Highest Certainty
Tesamorelin
★ FDA-Approved Phase III RCT
Falutz 2010 (n=412), Stanley 2014; Cochrane-consistent evidence base; FDA NDA approval 2010 for HIV-associated lipodystrophy. Only FDA-approved compound in PeptideReport.ai library.
Level IIb · Moderate Certainty
AOD-9604
Phase II Clinical Data
Phase IIa/IIb obesity trials (Heffernan 2001; Ng 2000); FDA did not approve for metabolic syndrome indication despite Phase II data — regulatory bar not cleared but human safety and preliminary efficacy data exists. Mechanistic GRAS status granted.
Level IIb · Moderate Certainty
CJC-1295 (No-DAC)
Small Human Trials
Teichman 2006 (JCE&M) — small Phase I/II human pharmacokinetic and GH pulse data. Mechanism well-characterized. Limited body composition endpoint RCT data; extrapolated from GHRH analogue class.
Level IV · Lower Certainty
BPC-157
Animal Models + Case Reports
Extensive rodent data (Sikiric, 1990s-2020s); no published human RCT for metabolic indications. FDA IND application filed (per Sikiric lab) but not approved as of 2026. Case series data available in GI healing context.
Level V · Preclinical Only
MOTS-c
Mouse Studies · Phase I Safety Only
Lee 2015 (Cell Metabolism) established the foundational AMPK mechanism in mice. One Phase I human safety study (unpublished/limited access). No human efficacy data for metabolic endpoints. The most uncertain compound in this hub despite compelling mechanism.
Highest Evidence Gap in PeptideReport.ai Library
The 4-tier evidence gap between Tesamorelin (Level I) and MOTS-c (Level V) within a single hub is the largest evidence disparity across any hub in the PeptideReport.ai compound library. A practitioner using MOTS-c in a metabolic protocol should explicitly document that the compound has no human efficacy data and is being used based on mechanistic plausibility alone (AMPK/mitochondrial pathway). This honest characterization is the minimum evidentiary standard for informed consent — the compelling mouse data does not substitute for human evidence in a clinical setting.
Laboratory Monitoring
Metabolic Monitoring Framework
Metabolic peptide protocols require systematic body composition and laboratory monitoring that extends beyond the endocrine panel used in Longevity Hub protocols. The addition of direct body composition measurement (DEXA or similar) and detailed lipid and glucose kinetics monitoring reflects the metabolic endpoint specificity of these compounds. Monitoring requirements vary by compound — Tesamorelin requires IGF-1 monitoring; AOD-9604 and MOTS-c do not; all require fasting glucose and lipid panel.
3-month glycemic average. GH stimulatory compounds are contraindicated in uncontrolled diabetes (HbA1c >8.0%). Target HbA1c <5.7% (non-diabetic range) for unconstrained metabolic peptide use; 5.7–6.4% (prediabetic) requires enhanced glucose monitoring.
Comprehensive Lipid Panel
All Compounds
Total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C. Tesamorelin reduces triglycerides significantly (2 mg/dL mean in RCTs) — baseline establishes change attribution. AOD-9604 lipolytic products may transiently affect triglycerides.
IGF-1 (Age-Referenced)
Tesamorelin, CJC-1295
Required for GHRHR agonists — IGF-1 rises with tesamorelin and CJC-1295 administration. Target: low-normal for age (NEVER upper quartile — upper-quartile IGF-1 carries colorectal/prostate cancer risk signal). IGF-1 not required for AOD-9604 or MOTS-c (neither elevates IGF-1).
DEXA Scan / Body Composition
All (especially AOD-9604, Tesamorelin)
Gold standard for body composition baseline: total fat mass, lean mass, visceral adipose tissue (VAT) estimate, regional fat distribution. DEXA is required to attribute changes to compound vs. diet/exercise. Without baseline DEXA, clinical endpoint attribution is impossible for body composition compounds.
Waist Circumference + WHtR
AOD-9604, Tesamorelin, MOTS-c
Simple anthropometric proxy for visceral adiposity when DEXA is unavailable. Waist-to-Height Ratio (WHtR) >0.5 = elevated metabolic risk in most populations. Serial measurements track visceral fat response to compound. Less precise than DEXA but cost-accessible for all practice settings.
CMP (Comprehensive Metabolic Panel)
All Compounds
Liver function (ALT, AST, ALP, bilirubin), kidney function (BUN, creatinine, eGFR), electrolytes. BPC-157 GI applications require liver enzyme baseline. All compounds lacking long-term human safety data warrant CMP baseline for organ function characterization.
Thyroid Panel (TSH, Free T4)
Tesamorelin, CJC-1295
GH axis activation can reduce TSH and affect thyroid hormone conversion (T4→T3 via type I deiodinase). Pre-existing subclinical hypothyroidism should be addressed before initiating GH-stimulatory compounds — hypothyroidism blunts GH response and confounds metabolic endpoints.
Body Composition Endpoint Reference
Metric
Assessment Method
Expected Change (Best Data)
Timeline
Primary Compound
Visceral Adipose Tissue (VAT)
DEXA, CT cross-section, MRI
15–20% VAT reduction (Tesamorelin Phase III); AOD-9604 data varies by trial
3–6 months continuous
Tesamorelin (best data); AOD-9604
Total Body Fat %
DEXA (primary); BIA (secondary)
1–3% total body fat reduction over 6 months; highly variable by diet/exercise co-intervention
3–6 months
Tesamorelin, AOD-9604, CJC-1295
Lean Body Mass
DEXA
Preservation or modest increase (+0.5–2 kg over 6 months); GH axis compounds lean-preserving
Neutral to slight worsening with GH-axis compounds; MOTS-c expected improvement (preclinical only)
6–12 weeks
All; monitor for worsening
IGF-1
Serum IGF-1 (AM, fasting)
Target: low-normal for age — NEVER upper quartile; reduce dose if IGF-1 >300 ng/mL or upper-age-quartile
6 weeks post-initiation
Tesamorelin, CJC-1295 only
Clinical Risk Management
GH-Axis Insulin Resistance Risk Stratification
The most common metabolic complication of GH-stimulatory compounds (Tesamorelin, CJC-1295) is worsening insulin resistance. HOMA-IR at baseline and during follow-up should drive clinical decision-making — not just compound selection, but dose adjustment, adjunct co-administration, and monitoring frequency. This framework provides actionable decision rules at each HOMA-IR tier.
Low Risk
<1.5
HOMA-IR
Optimal Insulin Sensitivity
HOMA-IR < 1.5 — Full GH-Axis Protocols Appropriate
Full-dose GH-axis compounds appropriate — Tesamorelin 2 mg/day; CJC-1295 per standard protocol
Fasting glucose + HOMA-IR monitoring at 6 weeks, then quarterly
MOTS-c adjunct optional — add only if mitochondrial optimization is a co-stated goal
No dose modification warranted at baseline; trigger modification if HOMA-IR rises above 2.0 on follow-up
GH-axis compounds appropriate with enhanced glucose monitoring frequency — monthly for first 3 months rather than quarterly
Consider MOTS-c adjunct — AMPK activation may partially offset GH-driven insulin resistance worsening (preclinical rationale only; no human data confirming this protective effect)
HbA1c baseline mandatory; repeat at 12 weeks
If HOMA-IR rises above 2.5 at 6-week check: trigger elevated-tier protocol immediately — do not wait for 12-week visit
Physician-directed dose reduction of GH-axis therapy should be considered at this threshold, or substitution of AOD-9604 as primary fat-loss agent (no IGF-1 elevation, no IR worsening mechanism)
MOTS-c adjunct strongly recommended alongside any GH-axis compound at this threshold
Intermittent, physician-supervised dosing schedules are generally preferred over continuous dosing at this risk tier
Dietary carbohydrate timing co-intervention — carbohydrate restriction in the 2 hours surrounding injection may partially offset GH-driven post-injection glucose elevation
Fasting glucose bi-monthly; HOMA-IR at 6 and 12 weeks; HbA1c at 12 weeks mandatory
HOMA-IR > 2.5 — GH-Axis Contraindicated as First-Line
Avoid GH-axis compounds as first-line metabolic intervention — risk of clinically meaningful glucose metabolism worsening outweighs body composition benefit at this threshold
First-line approach: AOD-9604 (fat loss via β3-AR/HSL, no IGF-1, no IR liability) + MOTS-c (AMPK/insulin sensitivity; preclinical evidence only)
HOMA-IR = Fasting Glucose (mmol/L) × Fasting Insulin (μIU/mL) ÷ 22.5 — in US units: [Glucose (mg/dL) ÷ 18] × Insulin (μIU/mL) ÷ 22.5. Collect fasting sample (8h minimum), morning draw. HOMA-IR is the validated primary insulin resistance surrogate for this monitoring framework. C-peptide characterization may be warranted in patients with suspected insulin secretory defects; euglycemic clamp is the gold standard but not practical for routine monitoring.
Protocol Architecture
Cross-Tier Combination Protocols
The 4-tier mechanism architecture enables intelligent combinations without redundant signaling. Each protocol below combines compounds from different tiers — Tier 1 mitochondrial, Tier 2 adipocyte receptor, Tier 3 GH-axis, Tier 4 systemic healing. Same-tier combinations (e.g., Tesamorelin + CJC-1295) are generally avoided: they add IGF-1 elevation without additive fat loss benefit and compound the insulin resistance risk.
Tesamorelin drives VAT reduction via GH-IGF-1 axis (15–20% VAT reduction; Phase III RCT data). MOTS-c targets AMPK at the mitochondrial level — the mechanism most likely to partially offset GH-driven insulin resistance worsening. Tier 3 and Tier 1 act on entirely separate pathways; there is no receptor competition. Rationale: maximize the primary endpoint (VAT reduction) while addressing the primary complication of GH-axis therapy (IR worsening). Best-evidence + highest-tier for metabolic syndrome with visceral adiposity as the primary phenotype.
Monitor: HOMA-IR + fasting glucose at 6 weeks; IGF-1 at 6 weeks (target low-normal); HbA1c at 12 weeks. DEXA at 3 months for VAT endpoint attribution.
B
Body Composition Protocol
Fat loss + lean mass preservation, athletic/performance phenotype
CJC-1295 + Ipamorelin engage dual GHRHR + GHS-R1a receptors for synergistic pulsatile GH (see Longevity Hub dual-pathway synergy). AOD-9604 adds a third lipolytic mechanism at the adipocyte β3-AR level independently — no additional IGF-1 contribution, no mechanism overlap with the GHRHR/GHS-R1a pair. Three compounds, two tiers, three mechanistically distinct fat-loss pathways. Note: the triple combination carries meaningful IGF-1 elevation risk — check at 6 weeks and target low-normal.
Monitor: IGF-1 at 6 weeks (critical — three independent GH-promoting vectors); HOMA-IR quarterly; DEXA at 12 weeks for body composition endpoint.
The only fully IGF-1-free combination in this hub. BPC-157 addresses gut barrier dysfunction and inflammatory metabolic burden (Tier 4 systemic healing via NO/VEGF/GHR sensitization). MOTS-c targets upstream cellular energy dysregulation via AMPK (Tier 1 mitochondrial). Appropriate when GH-axis compounds are contraindicated (HOMA-IR >2.5, uncontrolled diabetes, IGF-1 sensitivity concerns, active malignancy). Both compounds carry the lowest evidence tiers in the hub — informed consent must explicitly characterize both as experimental with preclinical-only rationale.
Monitor: HOMA-IR at 8 and 16 weeks; CMP baseline + at 12 weeks (BPC-157 GI/hepatic monitoring); clinical symptom assessment monthly. No IGF-1 monitoring required.
D
Insulin-Resistant Profile Protocol
HOMA-IR >2.0; GH-axis contraindicated or undesirable
When HOMA-IR >2.0 makes GH-axis compounds inadvisable, this IGF-1-free combination targets fat loss (AOD-9604 via β3-AR/HSL lipolysis — Phase II human data) alongside insulin sensitivity improvement (MOTS-c via AMPK — preclinical only). No GH-IGF-1 axis engagement; no IR worsening mechanism. Intended as a transitional protocol to address the metabolic phenotype while HOMA-IR normalizes, then reassess GH-axis candidacy at 90 days. Sets the patient up for Protocol A or B when the metabolic risk threshold is met.
Monitor: HOMA-IR at 8 and 16 weeks (primary transitional endpoint); fasting glucose monthly. No IGF-1 monitoring required. Reassess GH-axis candidacy when HOMA-IR <2.0 is confirmed.
Same-Tier Combination Caution
Do not combine compounds from the same mechanism tier without clear rationale. Tesamorelin + CJC-1295 engage the same GHRHR receptor — this produces additive IGF-1 elevation without additional VAT reduction benefit and compounds the insulin resistance liability, with no supporting clinical data. The 4-tier architecture is the combination guide: cross-tier protocols are the clinically productive combinations; same-tier combinations are mechanistically redundant and carry compounded risk.
Clinical Decision Support
Compound Selection Matrix
When the primary goal is metabolic optimization, the compound selection decision should be driven by the specific phenotype being addressed, the practitioner's evidence comfort threshold, and the route of administration that fits the patient's context. This matrix is designed to support the initial compound selection conversation.
Clinical Goal
First-Choice Compound
Evidence Basis
Route
Key Consideration
Visceral fat reduction (primary goal)
Tesamorelin
Level I (Phase III RCT)
SC 2mg daily
Only FDA-approved option; off-label in non-HIV patients; raises IGF-1 (monitor at 6 weeks); contraindicated in active malignancy
Fat loss without IGF-1 elevation
AOD-9604
Level IIb (Phase II)
SC or oral
No GHR binding; no IGF-1 elevation; FDA-rejected for metabolic syndrome (efficacy bar not met in Phase III); mechanism is sound but regulatory history is important context
Body composition (fat loss + lean mass)
CJC-1295 No-DAC + Ipamorelin
Level IIb + IIb combination
SC nightly
Dual-receptor synergy parallel to Sermorelin+Ipamorelin (see Longevity Hub); raises IGF-1; target low-normal; No-DAC formulation critical to preserve pulsatile physiology
Insulin sensitivity / mitochondrial optimization
MOTS-c
Level V (preclinical only)
SC
Most compelling mechanism (AMPK); least evidence; no human efficacy data; informed consent must explicitly characterize as experimental with preclinical rationale only
GI-metabolic axis / healing + metabolic support
BPC-157
Level IV (animal + case series)
Oral or SC
Cross-listed from Healing Hub; primary compound for GI mucosal healing; metabolic benefits are secondary; no human RCT data in any indication as of 2026
GH axis + metabolic (highest evidence, most studied)
Tesamorelin (or Sermorelin + Ipamorelin from Longevity Hub)
Level I / IIb-IIb
SC nightly
When metabolic goals overlap with longevity goals (body composition + anti-aging), the Longevity Hub sermorelin+ipamorelin combination is often the appropriate cross-hub protocol — metabolic hub compounds are specialized for when that combination is insufficient or for specific phenotypes (pure visceral fat, insulin resistance)
Safety Reference
Safety Overview by Compound
The metabolic hub has a heterogeneous safety database — Tesamorelin has the most thoroughly characterized safety profile (Phase III + post-marketing surveillance) while MOTS-c and BPC-157 have limited to no human safety data. Each compound's safety characterization should be communicated to patients at the level corresponding to its evidence base.
Insulin Resistance (GH-axis compounds)
Monitor Carefully
GH elevation (Tesamorelin, CJC-1295) can worsen insulin resistance, particularly in patients with pre-existing metabolic syndrome or elevated HOMA-IR. Tesamorelin's Phase III data showed significant glucose elevation in some subjects despite VAT reduction. HbA1c and fasting glucose at 3 months are mandatory for all GH-axis compound protocols.
Fluid Retention / Edema
GH-axis Compounds
GH-driven sodium retention causes mild edema in 10–30% of users, particularly at higher doses. Usually mild and self-limiting; dose reduction is the primary management. More pronounced with GH itself than with GHRH analogues, but present with Tesamorelin and CJC-1295. Monitor for new-onset peripheral edema at each visit.
IGF-1 Elevation (Upper-Quartile Risk)
Tightly Managed
Upper-quartile IGF-1 is epidemiologically associated with colorectal, prostate, and pre-menopausal breast cancer. GH-axis compounds must target low-normal IGF-1 for age — NEVER maximum elevation. Check at 6 weeks; if >300 ng/mL or above age-stratified normal upper limit, reduce dose immediately.
AOD-9604 Regulatory History
FDA Rejected (Phase III)
FDA rejected AOD-9604 for metabolic syndrome in 2007 after Phase III data did not meet efficacy endpoints, despite Phase II signals. This regulatory history is important context — the compound was not rejected for safety, but for failing to demonstrate sufficient efficacy at the Phase III scale. The mechanism remains sound; the clinical translation was insufficient for NDA approval.
MOTS-c — No Human Safety Database
Uncharacterized
Beyond one Phase I safety study (limited published data), MOTS-c has no human safety database accessible in Western peer-reviewed literature. Animal toxicology data is the primary safety reference. This is the highest uncertainty compound in this hub and requires the most explicit informed consent language regarding experimental status.
BPC-157 — Tumor Promotion Controversy
Active Scientific Debate
BPC-157's VEGF upregulation and angiogenic effects have raised theoretical concerns about tumor promotion — VEGF is a key pathway in tumor neovascularization. The same VEGF/NO upregulation that promotes tissue healing could theoretically support existing occult tumor growth. No human clinical cancer signal has been documented, but the mechanism warrants caution in any patient with active or recent malignancy history. This is an area of genuine scientific controversy within the research community.
Tesamorelin Contraindications (FDA Label)
Per the FDA-approved Egrifta SV® label: Contraindicated in patients with: active malignancy; disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary irradiation; active underlying intracranial lesion; pregnancy (may cause fetal harm). These are label-specific contraindications from the only FDA-approved compound in this hub and should be applied as absolute contraindications, not as considerations.
Common Questions
Metabolic Research Hub: Frequently Asked Questions
These questions address the Metabolic Research Hub as a whole — how it is organized, how its compounds differ in regulatory and evidence status, and how to interpret the category before consulting individual compound profiles.
What metabolic peptides does the PeptideReport.ai Metabolic Research Hub cover?
This hub covers five peptide-based compounds — MOTS-c, AOD-9604, Tesamorelin, BPC-157, and CJC-1295 — alongside three GLP-1/GIP-class metabolic drugs: Semaglutide, Tirzepatide, and Retatrutide. Together these span mitochondrial signaling, adipocyte lipolysis, the GH-IGF-1 axis, and incretin receptor agonism as distinct mechanistic approaches to body composition and metabolic health.
Which metabolic compounds on this hub are FDA-approved versus investigational?
Semaglutide and Tirzepatide are FDA-approved for type 2 diabetes and chronic weight management, and Tesamorelin is FDA-approved specifically for visceral fat reduction in HIV-associated lipodystrophy. AOD-9604, MOTS-c, and BPC-157 are unapproved research compounds with no FDA authorization for human use, and Retatrutide remains investigational, with Phase III trials ongoing and a BLA planned for Q1 2027. Using an FDA-approved drug outside its approved indication — such as Tesamorelin for non-HIV visceral fat — is considered off-label use.
How effective are GLP-1-class drugs like semaglutide and tirzepatide for weight management, according to clinical trials?
In the Phase III STEP and SUSTAIN trial programs, semaglutide produced average weight loss in the mid-teens percentage range along with durable HbA1c reduction. Tirzepatide's SURMOUNT program showed an even larger average effect size, which researchers attribute to its added GIP receptor co-agonism. Individual results vary considerably across trial participants, and this information describes published trial outcomes rather than a guarantee of any individual's results.
Why does the evidence quality vary so widely across compounds in this hub?
This hub spans the full range of the PeptideReport.ai evidence framework, from Level I FDA-approved Phase III data (Tesamorelin, Semaglutide, Tirzepatide) to Level IIb human trial data (AOD-9604, CJC-1295, Retatrutide) to Level IV animal and case-series data (BPC-157) to Level V preclinical-only data (MOTS-c). This is the widest evidence disparity of any hub in the PeptideReport.ai library, and each compound's evidence tier should inform how it is discussed and understood.
What is the biggest risk with unapproved research compounds like MOTS-c, AOD-9604, or BPC-157?
The primary risk is the absence of human efficacy and, in MOTS-c's case, of any meaningful human safety data — MOTS-c is supported by mouse studies and a single limited Phase I safety trial, with no confirmed human metabolic benefit. AOD-9604 has Phase II human data but was rejected by the FDA at Phase III for insufficient efficacy, and BPC-157's VEGF-driven angiogenic mechanism has raised unresolved theoretical concerns about tumor promotion. None of these compounds should be treated as clinically equivalent to the FDA-approved options in this hub.
Do the compounds on this hub require a prescription?
Semaglutide, Tirzepatide, and Tesamorelin are FDA-approved prescription medications that require evaluation and oversight by a licensed physician. MOTS-c, AOD-9604, BPC-157, and Retatrutide are not FDA-approved for human use and have no established prescribing pathway; this hub presents them for research and educational purposes only and does not recommend, encourage, or endorse their use.
About the Author
Dr. Scott DelBoccio, DMD
Physician-Researcher · PeptideReport.ai · Founder
Dr. Scott DelBoccio, DMD, is the founder and physician-researcher behind PeptideReport.ai. His work focuses on synthesizing emerging peptide research literature into E-E-A-T–compliant clinical education for healthcare practitioners. All compound profiles at PeptideReport.ai are physician-authored, evidence-graded, and designed to meet the evidentiary standards appropriate for YMYL health content. Research profiles do not constitute medical advice and are intended for educational and informational purposes only.
Research Resource Disclaimer. This content is authored by Dr. Scott DelBoccio, DMD, and is intended for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The compounds covered in this hub include both FDA-approved pharmaceuticals (Tesamorelin/Egrifta SV®) and unapproved research compounds not evaluated by the U.S. FDA for safety and efficacy in the general population. FDA-approved indications are explicitly noted; all other clinical applications referenced are off-label or investigational. All clinical decisions regarding peptide research compounds should be made in consultation with a licensed physician familiar with the patient's complete medical history. This hub does not recommend, encourage, or endorse the use of any compound.